A pilot study of tofacitinib for refractory Behçet's syndrome

Jinjing Liu; Yunxia Hou; Luxi Sun; Chaoran Li; Lu Li; Yan Zhao; Xiaofeng Zeng; Fengchun Zhang; Wenjie Zheng

doi:10.1136/annrheumdis-2020-217307

A pilot study of tofacitinib for refractory Behçet's syndrome

Ann Rheum Dis. 2020 Nov;79(11):1517-1520. doi: 10.1136/annrheumdis-2020-217307. Epub 2020 May 27.

Authors

Jinjing Liu^{1

2}, Yunxia Hou³, Luxi Sun^{1

2}, Chaoran Li^{1

2}, Lu Li^{1

2}, Yan Zhao^{1

2}, Xiaofeng Zeng^{1

2}, Fengchun Zhang^{1

2}, Wenjie Zheng^{4

2}

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
² Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
³ Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
⁴ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China wenjzheng@gmail.com.

PMID: 32461206
DOI: 10.1136/annrheumdis-2020-217307

No abstract available

Keywords: Behcet's disease; DMARDs (synthetic); treatment.

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Behcet Syndrome / drug therapy*
Female
Humans
Male
Middle Aged
Pilot Projects
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Pyrroles / therapeutic use*

Substances

Piperidines
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
tofacitinib